cells, including Oligodendrocytes and Astrocytes. Based on its differentiation technologies, the company advances two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells for the diabetes program and astrocytes are differentiated into beta cells for the ALS program, with the goal of implanting them into patients, and affecting diseases progression. The company’s technology is designed to screen compounds automatically and quantify the readouts using a cell-based High Content Screening (HCS) system.

Kadimastem partners with pharmaceutical companies to screen potential drug compounds on its stem-cell derived cells. It produces a number of human cell and tissue systems that constitute screening platforms to search for agonists or antagonists of specific biological processes, with the aim of developing safe drugs.

Kadimastem is based in Nes Ziona, Israel.